{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-060221","form_type":"8-K","ticker":"CTMX","cik":"0001501989","company_name":"CytomX Therapeutics, Inc.","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.286573+00:00","generated_at":"2026-06-08T14:46:08.998835+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CytomX Q3 revenue $26.4M, cash $194.1M; pipeline milestones on track","bullets":["Revenue $26.4M vs $11.1M YoY; cash $194.1M (includes ~$30M from BVF financing, $16.8M Q3 burn).","R&D expense $16.4M (-46% YoY); G&A $6.8M (-35% YoY); no net income or EPS disclosed.","CX-904 Phase 1a dose escalation data expected H1 2024; backfilling cohorts initiated Q4 2023.","CX-2051 IND filing by end of 2023; Phase 1 in solid tumors in 2024 with mCRC priority.","BMS-986288 Phase 2 ongoing; proof-of-concept data in MSS CRC and NSCLC expected in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-060221","json":"https://secwatch.observer/filing/0000950170-23-060221.json","markdown":"https://secwatch.observer/filing/0000950170-23-060221.md","text":"https://secwatch.observer/filing/0000950170-23-060221.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501989/000095017023060221/0000950170-23-060221-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501989/000095017023060221/ctmx-20231107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T14:46:08.998835+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"80e9534b80c2e4b9cc916130ad04919377767116","claim":"CytomX Therapeutics, Inc. reported financial results for third quarter 2023.","evidence_excerpt":"On November 7, 2023, CytomX Therapeutics, Inc., a Delaware corporation (the “Company”) issued a press release reporting its unaudited financial results as of and for the three and nine months ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501989/000095017023060221/0000950170-23-060221-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}